Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies

PURPOSE: To define dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of capecitabine with fixed-dose rate (FDR) gemcitabine. PATIENTS AND METHODS: Eligible adults (advanced solid tumor; performance status ≤ 2) received capecitabine 500mg/m(2) PO BID days 1-14 and FDR gemcitabine (...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Attia, Steven, Morgan-Meadows, Sherry, Holen, Kyle D., Bailey, Howard H., Eickhoff, Jens C., Schelman, William R., Traynor, Anne M., Mulkerin, Daniel L., Campbell, Toby C., McFarland, Thomas A., Huie, Michael S., Cleary, James F., Tevaarwerk, Amye J., Alberti, Dona B., Wilding, George, Liu, Glenn
Formato: Artigo
Lenguaje:Inglês
Publicado: 2008
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2676212/
https://ncbi.nlm.nih.gov/pubmed/18841362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-008-0844-1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares